000125556 001__ 125556
000125556 005__ 20240228143316.0
000125556 0247_ $$2doi$$a10.1002/hon.2199
000125556 0247_ $$2pmid$$apmid:25784529
000125556 0247_ $$2ISSN$$a0278-0232
000125556 0247_ $$2ISSN$$a1099-1069
000125556 0247_ $$2altmetric$$aaltmetric:3801749
000125556 037__ $$aDKFZ-2017-01682
000125556 041__ $$aeng
000125556 082__ $$a610
000125556 1001_ $$aBreitkreutz, Iris$$b0
000125556 245__ $$aDose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
000125556 260__ $$aNew York, NY [u.a.]$$bWiley Interscience$$c2016
000125556 3367_ $$2DRIVER$$aarticle
000125556 3367_ $$2DataCite$$aOutput Types/Journal article
000125556 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524213019_3007
000125556 3367_ $$2BibTeX$$aARTICLE
000125556 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125556 3367_ $$00$$2EndNote$$aJournal Article
000125556 520__ $$aTherapeutic options in heavily pretreated relapsed/refractory multiple myeloma patients are often very limited because of impaired bone marrow function. Bendamustine is effective in multiple myeloma and has a favourable toxicity profile. We hypothesized that dose-intensified bendamustine (180 mg/m(2) , day 1 and 2) followed by autologous blood stem cell support (ASCS) would improve bone marrow function with low post-transplant toxicity in patients with severely impaired haematopoiesis. We analyzed 28 consecutive myeloma patients, with a median of three prior lines of therapy (range 2-7), who had relapsed from the last treatment with very limited bone marrow function and were therefore ineligible for conventional chemotherapy, novel agents or trial enrolment. Dose-intensified bendamustine with ASCS improved haematopoiesis as reflected by increased platelet counts (median 40/nl vs 94/nl, p = 0.0004) and white blood cell counts (3.0/nl vs 4.8/nl, p = 0.02) at day +100. The median time until engraftment of platelets (>50/nl) was 11 days (0-24 days) and of white cell counts (>1.0/nl) 0 days (0-24 days). At least, a minimal response was achieved in 36% of patients. The disease stabilization rate was 50% while the median progression-free survival rate was limited to 2.14 months. Most importantly, patients were once again eligible for alternative treatments including enrolment into clinical trials. We conclude that dose-intensified bendamustine followed by ASCS is safe and feasible for multiple myeloma patients with very limited bone marrow reserve. Copyright © 2015 John Wiley & Sons, Ltd.
000125556 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000125556 588__ $$aDataset connected to CrossRef, PubMed,
000125556 650_7 $$0981Y8SX18M$$2NLM Chemicals$$aBendamustine Hydrochloride
000125556 7001_ $$0P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aBecker, Natalia$$b1$$udkfz
000125556 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000125556 7001_ $$aKosely, Florentina$$b3
000125556 7001_ $$aHeining, Christoph$$b4
000125556 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b5$$udkfz
000125556 7001_ $$aEgerer, Gerlinde$$b6
000125556 7001_ $$aHo, Anthony D$$b7
000125556 7001_ $$aGoldschmidt, Hartmut$$b8
000125556 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b9$$eLast author$$udkfz
000125556 773__ $$0PERI:(DE-600)2001443-0$$a10.1002/hon.2199$$gVol. 34, no. 4, p. 200 - 207$$n4$$p200 - 207$$tHematological oncology$$v34$$x0278-0232$$y2016
000125556 909CO $$ooai:inrepo02.dkfz.de:125556$$pVDB
000125556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000125556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000125556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000125556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000125556 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000125556 9141_ $$y2016
000125556 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125556 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125556 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125556 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125556 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEMATOL ONCOL : 2015
000125556 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125556 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125556 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125556 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125556 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125556 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125556 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000125556 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000125556 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x1
000125556 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x2
000125556 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x3
000125556 980__ $$ajournal
000125556 980__ $$aVDB
000125556 980__ $$aI:(DE-He78)G330-20160331
000125556 980__ $$aI:(DE-He78)G170-20160331
000125556 980__ $$aI:(DE-He78)C060-20160331
000125556 980__ $$aI:(DE-He78)E010-20160331
000125556 980__ $$aUNRESTRICTED